

# Prescription Drugs: Market Research Report

<https://marketpublishers.com/r/P3A41D04CB2EN.html>

Date: July 2009

Pages: 1810

Price: US\$ 3,950.00 (Single User License)

ID: P3A41D04CB2EN

## Abstracts

This report analyzes the worldwide markets for Prescription Drugs in US\$ Billion by the following therapeutic class – Oncologics/ Cancer Drugs, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents, and Others.

The report provides separate comprehensive analytics for the US Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual forecasts are provided for each region for the period 2006 through 2015.

A five-year historic analysis is also provided for these markets.

The report profiles 292 companies including many key and niche players worldwide such as Abbott Laboratories, Allergan, Inc., Amgen, Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim Group, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Inc., Merck & Co. Inc., Merck Serono International S.A., Mylan, Inc., Novartis AG, Pfizer, Inc., Ranbaxy Laboratories Limited, Sanofi-Aventis SA, Sanofi Pasteur, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Watson Pharmaceuticals, Inc., and Wyeth.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations  
Disclaimers  
Data Interpretation & Reporting Level  
Quantitative Techniques & Analytics  
Product Definition and Scope of Study

### II. EXECUTIVE SUMMARY

#### 1. INDUSTRY OVERVIEW & OUTLOOK

Pharma Industry Hit by Economic Downturn

**Table 1.** Worldwide Prescription Drugs Sales: 2006-2015 (includes corresponding Graph/Chart)

The Regional Impact  
Emerging Markets to Drive Growth  
Biotechnology  
Biotech Bankruptcies Rife in the Current Economic Downturn  
Economic Downturn Takes Toll on R&D  
Outsourcing – A Mixed Bag  
Generics – The Bright Spot

**Table 2.** Increasing Share of Generics in the Global Pharmaceutical Market: 1995-2005 (In %) (includes corresponding Graph/Chart)

**Table 3.** Generics Share in Select Markets Worldwide – United States, Germany, UK, Spain, Japan, Italy, France, Finland, Denmark, The Netherlands, Norway, and Ireland (includes corresponding Graph/Chart)

Patent Expiries of Major Drugs: 2009-2012  
Patient Spending  
Operational Restructuring

Rising R&D Costs Call for Improved Efficiency  
Concerns Over Drug Safety and Side Effects Impede Sales  
Policy Issues Threaten Innovation  
Regulatory Glitches and High Costs Hinder Biogeneric Growth  
Opportunities Outside Drug Development  
Going Forward in Forward Integration  
Forward Integration into Diagnostics  
Opportunities in Healthcare  
Down the Distribution Chain

## **2. LEADING PHARMA COMPANIES AND DRUGS WORLDWIDE**

Pfizer Reigns Supreme...

**Table 4.** Leading Global Pharmaceutical Companies Worldwide by Sales (2008, 2007, and 2006) - Pfizer, GlaxoSmithKline, Novartis, Sanofi-Aventis, AstraZeneca, Roche, Johnson & Johnson, Merck & Co., Abbott and Eli Lilly - in US\$ Billion (includes corresponding Graph/Chart)

Leading Prescription Drugs Worldwide – Lipitor Leads the Way

**Table 5.** Leading Prescription Drugs Worldwide by Sales (2008, 2007, and 2006)- Lipitor, Plavix, Nexium, Seretide, Enbrel, Seroquel, Zyprexa, Remicade, Singulair and Levonox in US\$ Billion (includes corresponding Graph/Chart)

Oncology Tops Therapeutic Classes

**Table 6.** Leading Therapeutic Classes Worldwide by Sales (2008, 2007, and 2006)- Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others in US\$ Billion (includes corresponding Graph/Chart)

## **3. THERAPEUTIC DRUG CLASSES**

Cholesterol Reducers

Statins Lead the Way  
Emerging Leaders

**Table 7.** Leading Cholesterol Reducing Drugs Worldwide: Sales for the years 2004 through 2008 for Lipitor, Crestor and Vytorin (in US\$ Billion) (includes corresponding Graph/Chart)

Lack of Product Differentiation Mars Prospects  
Zocor – The First Statin to Switch to OTC  
Patent Expiries of Leading Cholesterol Reducers: 2009 and Beyond  
Oncologics  
Oncologics/ Cancer Drugs – Largest Therapeutic Class  
High Unmet Needs to Drive Growth  
Biologics to Reign Supreme  
Leading Drugs  
Leading Players  
Novel Therapies  
Respiratory Drugs  
Leading Brands and Players

**Table 8.** Leading Asthma Drugs Worldwide – Value Sales for the Years 2004-2008 for Seretide, Singulair, Symbicort and Pulmicort (in US\$ Billion) (includes corresponding Graph/Chart)

**Table 9.** Select COPD and Allergic Rhinitis Drugs Worldwide: Value Sales for the Years 2006-2008 for Spiriva, Nasonex and Zyrtec (In US\$ Billion) (includes corresponding Graph/Chart)

Patent Expiries of Leading Respiratory Drugs: 2008 and Beyond  
Antipsychotics  
Leading Schizophrenia Drugs  
Side Effects of Antipsychotics – A Major Issue  
Patent Expiries  
Patent Expiries of Leading Anti-Psychotic Drugs  
Zyprexa Continues to Lose Market Share  
Risperdal Sales to Plunge, Following its Patent Expiry  
Generics - Yet to Make a Mark in Antipsychotics

Increasing Use of Antipsychotics in Children Raises Concerns

Proton Pump Inhibitors

Patent Expiries of Leading Proton Pump Inhibitors: 2008 and Beyond

**Table 10.** Leading Proton Pump Inhibitors Worldwide – Value Sales for the Years 2004 through 2006 (US\$ Billion) - Nexium, Prevacid/Takepron, Protonix/Pantazol and AcipHex/Pariet (includes corresponding Graph/Chart)

Antidepressants

Patent Expiries of Leading Antidepressant Drugs Worldwide: 2005-2015

Erythropoietins

Competitive Landscape in the Global Erythropoietin Market

Leading Erythropoietin Drugs

**Table 11.** Leading Erythropoietin Drugs Worldwide – Annual Revenues for the Years 2004 through 2007 in US\$ Billion for Aranesp, Procrit/Epex, Epogen and NeoRecormon (includes corresponding Graph/Chart)

New and Pipeline Products

Biogenerics Pose Imminent Threat

Anti-Arthritics

**Table 12.** Leading Anti-arthritic Drugs Worldwide – Value Sales for Years 2006 through 2008 in US\$ Billion - Enbrel, Remicade, Rituxan and Humira (includes corresponding Graph/Chart)

Anti-Epileptics

Disease Statistics

Available Drugs

Generics to Take the Lead in Anti-Epileptic Market

**Table 13.** Leading Anti-Epileptic Drugs Worldwide: Value Sales for years 2005 through 2007 in US\$ Billion for Topamax, Lamictal, Depakote and Keppra (includes corresponding Graph/Chart)

Patent Expiries of Leading Anti-Epileptic Drugs  
New Launches  
Pipeline Drugs Bode Brighter Prospects  
Pipeline Drugs in Antiepileptics  
Calcium Channel Blockers  
Antidiabetics

**Table 14.** Leading Anti-diabetic Drug Sales Worldwide: Value Sales for Years 2005 through 2008 in US\$ Billion for Actos, Lantus, Avandia Franchise, Januvia and Byetta (includes corresponding Graph/Chart)

#### **4. MARKET DYNAMICS**

Pharma M&A Activity in 2008  
Aggressive M&A Deals by Japanese Companies  
Patent Expiries  
Patent Expiries for 2008 and 2007  
New Product Approvals

**Table 15.** New Drugs Approval from 2003-2008 (includes corresponding Graph/Chart)

**Table 16.** Biologics Approvals from 2003-2008 (includes corresponding Graph/Chart)

**Table 17.** Development of New Molecular Entities (Biological and Chemical) by Various Region/Country: Percentage Share Breakdown for the Periods 1998-2002 & 2003-2007 (includes corresponding Graph/Chart)

**Table 18.** Number of Compounds Under Development by Country/Region: Percentage Breakdown for the year 2007 (includes corresponding Graph/Chart)

New Molecular Entities (NMEs) Approved by FDA in 2008  
New Biological Entities Approved by FDA in 2008  
Research and Development

**Table 19.** R&D Investments by Pharmaceutical Sector in US and Europe: 2004-2007 (includes corresponding Graph/Chart)

Cost Pressures

R&D Productivity Slides Despite Increasing Investments

Aging Population Drives Demand

**Table 20.** World Demographic Trends: People Over 65 as a Percentage of Total Population by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific, and Latin America for years 2000, 2008, 2010, and 2020 (includes corresponding Graph/Chart)

## **5. PRESCRIPTION PHARMACEUTICALS - AN OVERVIEW**

Biologics

Evolution Of The Global Pharmaceutical Industry

Drug Development Process – FDA Perspective

Stages of Drug Development Process

Drug Discovery

Pre-Clinical Testing

Clinical Trials

Phase I Clinical Trial

Phase II Clinical Trial

Phase III Clinical Trial

New Drug Application

FDA Review

Phase IV Clinical Trials

FDA's Drug Safety Review – The Global Standard

## **6. SELECT THERAPEUTIC CLASSES**

Anti-arthritics

COX-2 Inhibitors

Antipsychotic Drugs

Anti-Ulcerants

Codeine & Combinations

Combination Drugs

Anti-Depressants

Selective Serotonin Reuptake Inhibitors (SSRIs)

Serotonin Noradrenaline Re-Uptake Inhibitors (SNRIs)

Serotonin Modulators (5-HT2 blockers)

Dopamine-norepinephrine Reuptake Inhibitors

Monoamine Oxidase Inhibitors (MAOIs)

Erythropoietin

Proton Pump Inhibitors

Seizure Disorder Drugs

Antihistamines

Calcium Channel Blockers

Cholesterol Reducers

## 7. MARKETING AND PROMOTIONS

**Table 21.** Promotional Spending by Major Pharma Companies (2006 and 2007) in US\$ Million – Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Sanofi-Aventis, Novartis, Eli Lilly, Schering-Plough, Johnson & Johnson, and Bristol Myers Squibb (includes corresponding Graph/Chart)

**Table 22.** Promotional Spending through Professional Detailing by Major Pharma Companies (2006 and 2007) in US\$ Million – Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Novartis, Sanofi-Aventis, Eli Lilly, Johnson & Johnson, Schering-Plough and Wyeth (includes corresponding Graph/Chart)

**Table 23.** Direct-To-Consumer Promotional Spending By Major Pharma Companies (2006 and 2007) in US\$ Million – Pfizer, GlaxoSmithKline, Merck, Bristol Myers Squibb, Sepracor, AstraZeneca, Schering-Plough, Sanofi-Aventis, Boehringer Ingelheim and Eli Lilly (includes corresponding Graph/Chart)

**Table 24.** E-Promotional Spending by Major Pharma Companies (2006 and 2007) in US\$ Million – Merck, GlaxoSmithKline, Johnson & Johnson, Pfizer, Shire, Eli Lilly, Schering-Plough, AstraZeneca and Sanofi- Aventis (includes corresponding Graph/Chart)

## 8. RECENT INDUSTRY ACTIVITY

Merck & Co. and Schering-Plough to Merge

Pfizer to Acquire Wyeth

CSL and Talecris Biotherapeutics to Withdraw Merger Agreement

AstraZeneca Partners with Merck to Analyze a New Combination of Anticancer Regimen

Sun Pharmaceutical Acquires Chattem



Novartis Acquires 25% Stake in Alcon  
Takeda Acquires Millenium Pharmaceuticals  
Teva Acquires Barr  
Invitrogen and Applied Biosystems Merge  
Eli Lilly Takes Over ImClone Systems  
Daiichi-Sankyo Acquires Controlling Stake in Ranbaxy  
Fresenius Acquires APP Pharmaceuticals  
TPG Acquires 50% Stake in SIA International  
GSK Acquires Sirtris  
Shire Acquires Controlling Interest in Jerini  
Boehringer Ingelheim to Purchase Actimis Pharmaceuticals  
Sanofi Pasteur Acquires Acambis  
Sanofi-Aventis Acquires Symbion  
Nordic and Avista Acquires ConvaTec  
King Pharmaceuticals Acquires Alpharma  
Shionogi Acquires Sciele  
Ranbaxy Inks Indian Marketing License for GLIADEL® with BioPro  
Tibotec Gains EC Approval for PREZISTA®'s Extended Indication  
GSK and Neptunus to Set up Joint Venture for Developing Flu Vaccines  
AstraZeneca Obtains TRO for Generic Pulmicort Respules  
Solvay Pharmaceuticals Enters Into a License Deal with Depomed  
AstraZeneca Enters into an Agreement with Par Pharmaceutical  
BioReliance and Provecs Enter into Agreement  
Cornerstone BioPharma and Critical Therapeutics Merge to Form Cornerstone Therapeutics  
GSK to Acquire Genelabs  
Lpath and Merck Serono Forge Partnership  
Allergan and Spectrum Ink Collaboration Deal for Bladder Cancer Drug  
EMD Signs Licensing and Collaboration Deal with Theratechnologies  
Medimetrics Receives License for Prescription Brands from Perrigo  
Forest Partners with Phenomix for Developing Diabetic Drug  
GSK Biologicals and AFFiRIS Sign Collaboration Agreement  
Sanofi-Aventis Strengthens R&D Operations in the Chinese Market  
UCB and Pfizer Establish Cyclofluidic  
Valeant Pharmaceuticals Completes Coria Laboratories Acquisition  
MedImmune Inks Agreement with Omniinvest over Reverse Genetic Technology  
Avidas Secures North American Rights of Crown's Dermatology Products  
Lilly Acquires Two Compounds for Early-Stage Tuberculosis Drug Pipeline  
Eli Lilly and Deciphera Enter into Collaboration and Licensing Deal

Roche, GlycArt and Genentech Sign Collaboration Agreement  
Cardinal Health Plans to Spin-Off Medical and Clinical Products Businesses  
Sanofi Pasteur Holding Acquires Acambis  
Eisai Plans NDA Submission for Insomnia Drug  
GlaxoSmithKline Enter into Strategic Alliance with Cellzome  
Ablynx and Merck Serono Sign Nanobodies® Agreement  
GlaxoSmithKline and Valeant Enter into Collaborative Agreement  
Noven Enters Supply and License Agreements with P&G Pharmaceuticals  
Eli Lilly Acquires SGX Pharmaceuticals  
Symbio Pharmaceuticals Enters into a License Agreement with Eisai  
Roche Sells Four Pharmaceutical Products to Meda AB  
AstraZeneca Joins Hands with Abbott for Co-Promotion of Crestor  
Gilead Sciences Inks Atripla®, HIV Drug Distribution Deal with Merck  
Eisai China Enters into Licensing Deal with Health Vision  
GSK and Harvard Stem Cell Institute Team Up for Drug Discovery  
Teva Acquires Bentley Pharmaceuticals  
Roche to Acquire ARIUS Research  
GlaxoSmithKline and Actelion Collaborate  
GSK Enters into Product Disinvestment Agreement with Aspen  
Lupin Forges Marketing Alliance with ASCEND for Suprax® Tablets  
Merck Serono Inks Multiple Sclerosis Drug-Development Deal with Bionomics  
European Commission Approves Kuvan® of Merck Serono  
GSK Collaborates with Mpex for Developing Anti-Bacterial Drugs  
Eli Lilly Announces Development & Licensing Agreement with TransPharma  
Mylan Obtains Exclusive Marketing Rights for Glatiramer from NATCO  
Sepracor Acquires Oryx Pharmaceuticals  
Mylan Takes Over Merck's Outstanding Generics Operations  
Gilead Acquires Cicletanine Business from Navitas  
King Pharmaceuticals to License Third Opioid Analgesic Product  
BioPhausia Acquires Prescription Pharmaceutical Offerings from AstraZeneca  
Ranbaxy Enters into Strategic Product Development Agreement with Merck  
EUSA Pharma Acquires Cytogen Corporation  
Dr. Reddy's Announces Two Major Acquisitions  
EUSA Divests Stake in Antibody Research and Oncology Product to IDD  
Sanofi Pasteur Delivers H5N1 Bulk Vaccine Antigen to HHS  
Ranbaxy Inks Strategic Business Alliance with Orchid  
Pfizer Settles Patent Litigation for Lipitor with Ranbaxy  
GSK Enters into Collaboration with Regulus Therapeutics  
Janssen to Launch J&J Group's New Drugs in Japan

Roche Alliance Partner Obtains Approval for Actemra in Japan  
Abbott Receives Japanese Approval for Rheumatoid Arthritis Drug, HUMIRA®  
Dr. Reddy's Completes Acquisition of Jet Generici Srl  
Eli Lilly, Transition Therapeutics Announce Licensing and Partnership Agreement  
Dr. Reddy's and 7TM Sign Drug Discovery Agreement for Selected Drug Targets  
Endo Pharmaceuticals Obtains US Rights for Novartis' Voltaren® Gel  
Pfizer to Take Over Serenex  
Sanofi-aventis, Amyris, iOWH Sign Semisynthetic Artemisinin Development Deal  
AstraZeneca Files sNDA for Depressive Disorder Drug, Seroquel XR™  
Forest, Mylan Amend Bystolic Agreement  
Fujifilm to Acquire Stake in Toyama Chemicals  
Graceway Takes Over Estrasorb  
Ranbaxy Announces De-Merger of New-Drug Discovery Research Unit  
AstraZeneca Inks Deal with Nomura Phase4 Ventures to Form Albireo  
Cellegy to Merge with Adamis Pharmaceuticals  
Mylan Reaches Accord with Novartis for Femara®'s Generic Product  
Dyax Signs Licensing and Development Agreements with Sanofi-aventis  
AstraZeneca Files for EU Approval of Seroquel XR™  
MedImmune Files Biologics License Application for motavizumab to FDA  
Farmavita, Belupo Sign Contract for Strategic Merger  
Pfizer Japan Secures Production and Marketing Approval for Champix®  
Eisai Enters into License Agreement with Abbott  
Eisai Takes Over MGI Pharma  
KV Pharmaceutical to Acquire Rights for Gestiva™ from Hologic  
Forest and Novoxel Enter into Licensing Agreement  
Dr. Reddy's Enters Settlement Agreement with Novartis for Exelon®  
Taisho and Pfizer Sign Agreement for TS-032  
Crucell Enters into Agreement with Sanofi Pasteur  
EMA Approves Second Biogeneric EPO, Retacrit  
Endo Pharmaceuticals Licenses AZ-003 from Alexza  
Schering-Plough and Centocor Modify Existing Distribution Agreement  
GSK and Santaris Pharma Collaborate in RNA Antagonists Research  
GSK Acquires Reliant Pharmaceuticals  
Eisai and Minophagen Ink In-Licensing Agreement for Liver Disease/ Allergic Disease Agents  
Bristol-Myers, Gilead Extend Agreement to Commercialize ATRIPLA® in Europe  
GSK and OncoMed Team Up for Antibody Therapeutics for Cancer Stem Cell Research  
GSK Allies with Galapagos for Antiviral and Antibacterial Development  
Eisai and BioArctic Ink Licensing Deal for BAN2401

Biogen and Neurimmune Join Hands to Develop Drugs for Alzheimer's Disease  
Sanofi-aventis Institutes GDC, Pharmaceutical Development Center in India  
AstraZeneca Obtains Pediatric Exclusivity for ARIMIDEX® from FDA  
Covance to Build High-Tech Drug Development Facility  
Schering-Plough Takes Over Organon BioSciences  
Takeda Launches Takeda San Francisco for Therapeutic Antibody Research  
GSK to Disinvest Lotronex®  
Gilead and LGLS Enter Global License Deal for Fibrotic Diseases Therapy  
Watson Acquires Andrx  
EPFL and Merck Serono Enter into Agreement  
Acura and King R&D Sign Licensing Agreement for Opioid Analgesic Products  
Eli Lilly Inks License Agreement with Glenmark Pharmaceuticals  
Wockhardt Takes Over Morton Grove Pharmaceuticals  
GSK Enters into Collaboration with Tolerx for Development of Novel Therapies  
Chugai Pharmaceuticals Obtains Approval for Tarceva in Japan  
Eli Lilly Announces Strategic Alliance with MacroGenics  
BMS, ImClone, Merck Serono Sign Erbitux® Agreement  
Wockhardt to Market Gnosis' SAME in India  
Alpharma Grants US License for Ketoprofen in Transfersome® Gel to IDEA  
Forest and Daiichi Sankyo Sign Contract to Co-Promote AZOR™  
Synta and GSK Sign Oncology Molecule Development Collaboration  
Cyclacel to Take Over ALIGN Pharmaceuticals and ALIGN Holdings  
GSK Inks Antiviral and Antibacterial Drug Development Deal with Anacor  
AMRI Enters into Research Collaboration with Cystic Fibrosis Foundation  
Mylan Takes over Merck Generics  
Kissei and Eisai Ink Licensing Deal for Glufast® Tablets  
AMRI Inaugurates New Research Unit in Hyderabad  
Eisai Inks Co-Promotion Deal with Salix for COLAZAL® Capsules  
Kowa and Teva to Establish Joint Venture Generic Drug Firm in Japan  
Nisshin Seifun Pulls Out of Joint Venture Nisshin Kyorin Pharmaceutical  
Chugai and Teijin Sign Agreement for Co-Development of Anti-Diabetic Drug  
MedImmune Inks Licensing Agreement with Novartis over Reverse Genetic Technology  
EUSA Acquires Assets of Innocoll  
Noven Enters Supply and License Agreements with P&G Pharmaceuticals  
Parion and Gilead Ink Deal to Develop Drug Candidates for Pulmonary Disease  
Noven Pharmaceuticals Acquires JDS Pharmaceuticals  
HHS Places an Order with GSK for Bulk H5N1 Antigen  
Synthon Completes Laboratorios Rider Acquisition  
Targacept Forges Partnership with GSK

Dong Wha Signs Alliance with P&G Pharma to Develop Treatment Molecules for Osteoporosis

Barr and Gedeon Richter Sign Pact over Generic Version of LAMISIL®

Santarus and Victory Pharma Enter Into Co-Promotion Agreement

AMRI Enters into Collaboration for Research with Achaogen

SCI Collaborates with High Q Foundation for Research on Huntington's Disease

MonoSol Rx Signs License Agreement with Strativa Pharmaceuticals

Eli Lilly to Launch Public-Private Partnership for Drug Research in Tuberculosis

Merck Serono and Bristol-Myers Squibb Ink Latin American Distribution Deal

Strides Arcolab to Take Over Bio-Fermentation Facility in Italy

Amgen to Take Over Alantos Pharmaceuticals

GlaxoSmithKline Establishes R&D Center in China

Wockhardt Acquires Negma Laboratories

Eisai Inks Exclusive Agreement with Solstice over NeuroBloc®

Ranbaxy to Acquire Be-Tabs Pharmaceuticals

Pfizer Obtains Health Canada Approval for LIPITOR in Reducing Myocardial Infarction

GSK Allies with Wellcome to Develop Antibacterials for Hospital-Contracted Infections

Bristol-Myers and Pfizer Ink Development and Commercialization Agreements

Cytos Biotechnology Grants Novartis with Global License for NicQb

Swiss Federal Register Adds ACOMPLIA® to Reimbursement List

Wockhardt to Introduce Syrio Pharma's B-Lift Product Range in India

Eisai Acquires Morphotex

Ranbaxy Obtains Approval for RAN™ Cefprozil Formulations in Canada

Roche Partners with Transgene to Focus on Therapeutic Vaccine Program

Cardinal Health Divests Pharmaceutical Technologies and Services Segment to Blackstone Group

Roche to Acquire BioVeris Corporation

Eli Lilly Acquires Hypnion

Roche Takes Over THP, Broadens Antibody Research Facility

Oxford BioMedica Enters into Development Deal with Sanofi-Aventis for TroVax®

Iroko Pharmaceuticals Acquires Rights to Indocin® and Aldomet® Products

Asahi Kasei Inks Licensing Agreement with Eisai Korea over Vasodilator Eril®

Merck Obtains EU Approval for JANUVIA™ Type 2 Diabetes Drug

Wockhardt Obtains FDA Approval for a Painkiller in the US

Ortho-McNeil Obtains Pediatric Extension for LEVAQUIN®

GlaxoSmithKline Obtains FDA Approval for Tykerb®

Terapia Ranbaxy Secures Marketing Approvals for 20 New Products

Shionogi to Develop and Market BioCryst's peramivir in Japan

Abbott and Eisai Amend Co-Promotion Agreement over HUMIRA® in Korea and Taiwan



Salix Acquires US Rights to Merck's Two Oral Suspension Products  
Takeda Expands Collaboration with XOMA in Potential Therapeutic Antibody Programs  
GSK Commences Phase III Clinical Trials of Tykerb®, a Post-Operative Lapatinib  
Roche Grants Glaxo with Exclusive Licensing Rights to its 'Orlistat' Drug  
GSK and HGS Commence Phase III Trials of LymphoStat-B® in SLE  
GSK and Fabre-Kramer Ink Global Deal for Gepirone ER  
Ranbaxy Signs Agreement with Zenotech for Biosimilars' Global Launch  
Ranbaxy Inks Long-Term R&D Deal with GSK  
Amgen Inks Three-year Aranesp Supply Agreement with Fresenius  
AstraZeneca to Take Over Arrow Therapeutics  
Eli Lilly Acquires ICOS Corporation  
Pfizer Plans to Takeover BioRexis  
Solvay Inks Licensing Deal with Jazz Pharmaceuticals for LUVOX®  
Eisai's 'Pariet®, 10mg Tablets' Receive Clearance for New Indication in Japan  
Eisai Receives EC Approval for Inovelon®  
Pfizer Receives Marketing Authorization for Sutent® in European Union  
GlaxoSmithKline Obtains Approval to Market Wellbutrin XR® in the Netherlands  
Forest Laboratories Acquires US Biopharmaceutical Company, Cerexa  
Mylan Laboratories Acquires 51.5% in Matrix  
DUSA Enters into an Agreement with Daewoong Pharmaceutical  
Penwest and Endo Amend Existing Contract on Opana® ER Collaboration  
Eli Lilly Licenses Glucokinase Activator Program from OSI Pharmaceuticals  
Graceway Pharmaceuticals Acquires 3M Pharmaceuticals Business  
Ranbaxy Obtains FDA Approval for Atenolol Tablets  
Gilead Sciences Acquires Myogen  
Gilead Sciences Acquires Raylo Chemicals

## **9. FDA APPROVALS FOR 2009, 2008 AND 2007**

## **10. A REVIEW OF SELECT PRODUCT INTRODUCTIONS IN THE PHARMA INDUSTRY**

Amgen Receives Approval for Nplate(R)...

Takeda Wins FDA Marketing Approval for ULORIC...

Novartis and MMV Launch Coartem® Dispersible

Ipsen and Medicis Receives FDA Approval for Dysport...

Centocor Receives FDA Approval for Simponi...

Wyeth Receives FDA Approval for PRISTIQ™...

GSK Receives FDA Approval for Promacta®...

Cephalon Receives FDA Approval for TREANDA...  
Adolor Receives FDA Approval For Entereg(R)...  
Lundbeck Introduces Xenazine\* (Tetrabenazine) Tablets  
Eisai US Receives FDA Approval for Banzel™ (Rufinamide)  
Progenics Receives FDA Approval for RELISTOR...  
J&J Receives Approval for Anti-HIV Medication 'Intelence'...  
Sandoz Launches Generic Fluoxetine Hydrochloride Capsules in US  
Sandoz Introduces Eplerenone Tablets  
Wockhardt Introduces Midazolam Injection in the US  
Dr. Reddy's Announces Launch of Generic Version of Imitrex® Tablets  
Arbor Pharmaceuticals Debuts NEOTIC™ for Middle- Ear Infections  
Promius Pharma Introduces EpiCeram® Emulsion  
Sandoz Unveils Generic Variant of Imitrex® Injection  
Dr. Reddy's Launches Redihaler™ and Combihale™  
Wyeth Launches Antihemophilic Factor, XYNTHA™  
Bayer Schering Releases YAZ®  
Mylan Introduces Nisoldipine ER Tablets in US  
Ranbaxy Launches Generic Omeprazole in US  
Ranbaxy Unveils Generic Equivalent of Amlodipine Tablets  
Teva Unveils Generic Equivalent of Lamictal® Tablets  
Eisai and Helsinn Healthcare Introduce ALOXI® Injection for Prevention of PONV  
Janssen and Patriot Unveil Authorized Generic Equivalent for Risperdal®  
Watson Releases Generic Equivalent of MARINOL®  
Sandoz Introduces Generic Form of Altace®  
Abbott Introduces Aluvia® Tablet in South Africa  
Dr. Reddy's Rolls-out Atacor-R  
Sandoz Unveils Generic Form of Maxipime®  
Tibotec Therapeutics Introduces New 600mg Dosage Strength for PREZISTA  
Ranbaxy Pioneers Launch of New Bio-Generic Recombinant Osteoporosis Injection  
Sandoz Introduces Generic Variant of Antizol® Injection  
Sun Pharmaceuticals Introduces Injection of Amifostine  
Sandoz Re-Launches Generic Form of Bactocill® Injection  
Sandoz Introduces Generic Form of Cipro® Injection  
Merck Serono Introduces Cyanokit® in Japanese Market  
Ranbaxy Launches INERSAN Tablets in India and Nepal  
Sandoz Launches Omnitrope™ Pen 5 with Liquid Cartridge  
Endo Pharmaceuticals to Introduce OPANA® ER in Three Dosage Strengths  
Sandoz Releases Generic Form of Camptosar®  
Sun Pharmaceuticals Unveils Pantoprazole Sodium DR Tablets

Dr. Reddy's Introduces Supanac®  
Watson Announces Launch of Clarithromycin 500mg Extended-Release Tablets  
GSK Announces FDA approval of Altabax™...  
Novartis' Tekturna HCT® Receives FDA Approval...  
GSK Receives FDA Approval for Tykerb®...  
Pfizer Receives FDA Approval for Selzentr...  
Ortho-McNeil Receives Approval for DORIBAX™...  
Merck Receives Approval for Isentress® ...  
BMS Wins FDA Approval for IXEMPRA™...  
Novartis' Tasigna® Receives FDA Approval...  
Mylan Receives FDA Approval for Bystolic...  
Roche's Mircera Secures FDA Approval...  
Eisai Launches New Dose Formulations of Aricept® Tablets in Japan  
Chugai Launches Tarceva® Tablet in Japan  
Sandoz Introduces Generic Version of Elocon® Lotion  
Ranbaxy to Introduce Tamsulosin Hydrochloride Capsules in Canada  
Watson Unveils Tilia™ Fe  
Ranbaxy Obtains Health Canada Approval for Ran®- Lisinopril Oral Tablets  
Sandoz Releases Generic Form of Delestrogen® Injections  
Sanofi and UCB Roll Out XYZAL® in US  
Sandoz Expands Range of Generic Augmentin® Drugs  
Sandoz Releases Generic Variant of Biaxin® for Oral Suspension  
Sandoz Introduces Generic Form of Penlac® Topical Solution  
Teva Releases Famciclovir Tablets  
Ranbaxy Introduces Roliflo OD in India  
Sandoz Introduces Generic Form of Toprol XL® 50Mg Extended Release Tablet  
Dr. Reddy's Introduces Glimy MP1 and Glimy MP2  
Sandoz Launches Approved Generic Equivalent of Lamisil®  
Ranbaxy Introduces Pravastatin Sodium 80mg Tablets in the US  
AstraZeneca Announces the Availability of Symbicort® pMDI  
Chugai and Maruho Announce the Launch of Oxarol® Lotion  
Ajinomoto and Eisai Jointly Launch 'Actonel® 17. 5mg Tablets'  
Sandoz Introduces Approved Generic Form of Lotrel®  
Dr. Reddy's Launches Ultravex™  
Wockhardt Unveils Zolpidem Tablets in the US  
Dr. Reddy's Introduces Reditux™  
Dr. Reddy's Secures Approval for Launching Zolpidem Tartrate Tablets  
Cipla Introduces Virenza Inhalation Capsules in India  
Ranbaxy Introduces Osovair in India



GlaxoSmithKline Introduces Coreg CR™  
Chugai Announces the Launch of Antiviral Agent, Copegus® Tablet  
Ranbaxy Unveils Generic Atorvastatin in Denmark  
Barr Unveils Generic 'PROSCAR®' Tablets  
Ranbaxy Introduces Niftran 100mg Capsules and Eligard 22. 5mg and 45mg  
Barr Releases METAGLIP™ Tablets  
SkinMedica Rolls Out Single-Dosage NeoBenz® Micro SD for Treating Acne  
Teva Rolls Out Generic Equivalent of Wellbutrin XI® Tablets  
Takeda Launches Takepron® I.V for Injection 30mg  
Takeda Launches duetact™ Combination Drug in USA  
Teijin Pharma Launches Bonalon® Tablet for Treating Osteoporosis

## **11. FOCUS ON SELECT GLOBAL PLAYERS**

Abbott Laboratories (USA)  
Allergan, Inc. (USA)  
Amgen, Inc. (USA)  
AstraZeneca (UK)  
Bayer AG (Germany)  
Bristol-Myers Squibb (USA)  
Boehringer Ingelheim Group (Germany)  
Dr. Reddy's Laboratories Ltd. (India)  
Eli Lilly and Company (USA)  
F. Hoffmann-La Roche Ltd. (Switzerland)  
Genentech, Inc. (USA)  
GlaxoSmithKline Plc (UK)  
Johnson & Johnson, Inc. (USA)  
Merck & Co. Inc. (USA)  
Merck Serono International S.A. (Switzerland)  
Mylan, Inc. (USA)  
Novartis AG (Switzerland)  
Pfizer, Inc. (USA)  
Ranbaxy Laboratories Limited (India)  
Sanofi-Aventis SA (France)  
Sanofi Pasteur (France)  
Takeda Pharmaceutical Company Limited (Japan)  
Teva Pharmaceutical Industries Ltd. (Israel)  
Watson Pharmaceuticals, Inc. (USA)  
Wyeth (USA)

## 12. GLOBAL MARKET PERSPECTIVE

**Table 25.** World Recent Past, Current & Future Analysis for Prescription Drugs Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 26.** World Historic Review for Prescription Drugs Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

**Table 27.** World 15-year Perspective for Prescription Drugs Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

**Table 28.** World Recent Past, Current & Future Analysis for Prescription Drugs Market by Therapeutic Class – Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets Independently Analyzed with Annual Sales in US\$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 29.** World Historic Review for Prescription Drugs Market by Therapeutic Class – Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets Independently Analyzed with Annual Sales in US\$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

**Table 30.** World 15-year Perspective for Prescription Pharmaceuticals Market by Therapeutic Class– Percentage Breakdown of Dollar Sales for Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

### III. MARKET

#### 1. THE UNITED STATES

##### A. MARKET ANALYSIS

Generics in the US

Biologics Post Highest Growth

Leading Prescription Drugs in the US

**Table 31.** Leading Prescription Drugs in the US by Value Sales (2008) in US\$ Billion - Lipitor, Nexium, Plavix, Advair Diskus, Seroquel, Singulair, Enbrel, Neulasta, Actos and Epogen (includes corresponding Graph/Chart)

Leading Therapeutic Classes in the US

**Table 32.** US Leading Therapeutic Classes by Revenue (2006-2008): Revenues for Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorders, Anti-Depressants, Angiotensin II Antagonists, Antineoplastic Monoclonal Antibodies, Erythropoietins, Anti-Arthritics and Oral Antiplatelets (in US\$ Billion) (includes corresponding Graph/Chart)

**Table 33.** US Leading Therapeutic Classes by Dispensed Prescriptions (2006-2008): Percentage Share Breakdown for Lipid Regulators, Combination Products, Anti-Depressants, ACE Inhibitors, Beta Blockers, Proton Pump Inhibitors, Seizure Disorders, Synthetic Thyroid Hormones, Calcium Blockers, Benzodiazepines, and Others (includes corresponding Graph/Chart)

Leading Players

**Table 34.** Leading Companies in the US Pharmaceutical Market (2006-2008): Percentage Breakdown of Value Sales for Pfizer, GlaxoSmithKline, Merck & Co., Johnson & Johnson, AstraZeneca, Amgen, Novartis, Hoffman-La Roche, Sanofi-Aventis, Eli Lilly and Others (includes corresponding Graph/Chart)

**Table 35.** US Pharmaceutical Market (2006-2008): Percentage Breakdown of

Dispensed Prescriptions for Teva Pharmaceuticals, Mylan Laboratories, Novartis, Watson Pharma, Pfizer, Barr Laboratories, Merck & Co., Mallinckrodt, Apotex, Qualitest, and Others (includes corresponding Graph/Chart)

Prescription Drug Spending

**Table 36.** Healthcare Spending in the US by Sector (2006) (includes corresponding Graph/Chart)

Increasing Share of Government in Prescription Drug Spending

**Table 37.** US Prescription Pharmaceutical Industry (2005 and 2006): Percentage Breakdown of Prescription Pharmaceutical Spending by Source for Private Insurance, Medicare, Medicaid, Out-of-Pocket and Other Public Spending (includes corresponding Graph/Chart)

Medicare Part D

Drug Price Regulations in the US

Pharmaceutical Marketing – A High Investment Area in the US

**Table 38.** Pharmaceutical Promotional Spending in the US by Type (2006-2008): Professionals-Directed Promotions and Consumer-Directed Promotions (in US\$ Billion) (includes corresponding Graph/Chart)

Major Distribution Channels

**Table 39.** Major Prescription Drugs' Distribution Channels in the US by Dispensed Prescriptions (2006-2008): Percentage Share Breakdown for Chain Stores, Independent Stores, Food Stores, Long-term Care, and Mail Order (includes corresponding Graph/Chart)

**Table 40.** Major Prescription Drugs' Distribution Channels in the US by Value Sales (2006-2008): Percentage Breakdown for Distribution Channel for Chain Stores, Mail Order, Independent Stores, Clinics, Non-government Hospitals, Food Stores and Other Channels (includes corresponding Graph/Chart)

Fewer Product Launches

Generic Penetration and PBMs Moderate Prescription Drug Price Growth

Co-payment Differentials to Increase Generic Substitution

High Prescription Drug Costs Drive Drug Re- Importation

Direct-to-Consumer Advertising

The 2006 Revision of Package Insert Format

Other Initiatives

Role of PBMs in the Pharmaceutical Supply Chain

Prescription Drug Pricing in US

Role of Mail-Order Pharmacies in Cost Containment

Product Launches

Strategic Corporate Developments

Select Key Players

## **B. MARKET ANALYTICS**

**Table 41.** US Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US\$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 42.** US Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US\$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

**Table 43.** US Recent Past, Current & Future Analysis for Prescription Pharmaceuticals by Therapeutic Class – Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, Others, Market Analyzed with Annual Sales in US\$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 44.** US Historic Review for Prescription Pharmaceuticals by Therapeutic Class – Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, Others, Market Analyzed with Annual Sales in US\$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

**Table 45.** US 15-Year Perspective for Prescription Pharmaceuticals by Therapeutic Class – Percentage Breakdown of Dollar Sales for Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II

Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, and Others for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

## **2. CANADA**

### **A. MARKET ANALYSIS**

Current and Future Analysis

Leading Drugs

**Table 46.** Leading Prescription Drugs in Canada in Terms of Number of Dispensed Prescriptions (2006 and 2007) in Million Scripts: Lipitor, Synthroid, Norvasc, Asaphen, Pantoloc, Crestor, Altace, Ratio-Salbutamol Hfa, Novo-Venlafaxine XR and Apo-Furosemide (includes corresponding Graph/Chart)

Major Therapeutic Classes

**Table 47.** Leading Therapeutic Classes in Canada in terms of Dispensed Prescription (2006 and 2007): Percentage Breakdown of Cardiovascular, Antipsychotics, Gastrointestinal/Genitourinary, Lipid Regulators, Hormones, Systemic Anti-infective, Analgesics, Diabetes Therapy, Diuretics, Neurological Disorders and Others (includes corresponding Graph/Chart)

Prescription Drugs Spending on the Rise

Private Sector Insurance Continues to Gain Popularity

Canadian Prescription Drugs Market- A Comparison with the US

Generic Sales to Outpace Branded Drugs Sales

Generics Market in Canada

Generics to Offer Potential Cost Savings

New Patented Drugs- Adding Costs but Little Value

Two-level Drug Approval Process in Canada

Policy Differences Affect Generic Substitution Among Provinces

Applied and Other Research Take Major Chunk of R&D Investments in Canada

**Table 48.** Investments in Research & Development in Canada (1998, 2001, 2004 and 2007): Percentage Breakdown by Research Type- Applied Research, Basic Research

and Other Research Areas (includes corresponding Graph/Chart)

Product Launches

Strategic Corporate Developments

## **B. MARKET ANALYTICS**

**Table 49.** Canadian Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US\$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 50.** Canadian Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US\$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

## **3. JAPAN**

### **A. MARKET ANALYSIS**

Current and Future Analysis

Generics Promotion in Japan

Ageing Population – A Prime Target

Competitive Landscape

**Table 51.** Leading Pharmaceutical Companies in Japan (2008): Percentage Breakdown of Revenues for Takeda Pharmaceuticals, Astellas Seiyaku, Dai-ichi Sankyo, Mitsubishi Tanabe, Chugai Seiyaku, Pfizer, Novartis, Eisai, GlaxoSmithKline and Otsuka Seiyaku (includes corresponding Graph/Chart)

**Table 52.** Leading Prescription Drugs in Japan (2006 and 2007): Value Sales in US\$ Million for Blopress, Diovan, Norvasc, Lipitor, Aricept, Epogin, Takepron, Leuplin, Micardis and Amlodin (includes corresponding Graph/Chart)

Cancer Drugs to Witness Robust Growth

Biennial Price Reduction to Impact Markets of Key Therapeutic Classes

Product Launches

Strategic Corporate Developments



Select Key Players

## **B. MARKET ANALYTICS**

**Table 53.** Japanese Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US\$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 54.** Japanese Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US\$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

## **4. EUROPE**

### **A. MARKET ANALYSIS**

Current and Future Analysis

Pharmaceutical Spending on the Rise

Mounting Healthcare Bills Boost Generic Drugs Consumption

Biogenerics Foray into Europe

SNRIs Likely to Replace SSRIs

Research and Development

**Table 55.** European Investments in Pharma Research & Development: 2005-2007 (includes corresponding Graph/Chart)

Europe - The Research and Production Hub for Vaccines Worldwide

Parallel Trade in Europe

New Rules to Offer Respite to Parallel Traders

Manufacturers Seek Greater Control Over Supply Chain

Pharmaceutical Industry Overview In Select Countries

France

Germany

Generics

Exports

Production

Prices



New Molecular Entities  
R&D Investments  
Parallel trade  
Genetically Manufactured Drugs

**Table 56.** German Genetically Manufactured Pharmaceuticals (2007): Percentage Breakdown of Sales by Type - Vaccines, Insulins, Interferons, Monoclonal Antibodies, Erythropoietin, and Others (includes corresponding Graph/Chart)

United Kingdom  
Spain  
Cost Containment Efforts  
Increased Promotion for Generics  
Re-launch of Reference Price System  
Distribution  
Italy  
Generics Gain Traction  
Sweden  
Greece  
Unique Pricing Model for Drugs  
Product Launches  
Strategic Corporate Developments  
Select Key Players

## **B. MARKET ANALYTICS**

**Table 57.** European Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US\$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 58.** European Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US\$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

## **5. ASIA-PACIFIC**

### **A. MARKET ANALYSIS**

## Current and Future Analysis

### Overview of Pharmaceutical Industries in Select Countries

#### India

##### Competitive Advantage

##### Number of FDA Approved Plants in India Vis-à-Vis Other Countries

##### Increasing Disposable Income Driving Consumption of Drugs

##### Generics to Surge Growth in Exports

##### Manufacturers Continue to Target Developed Markets

##### India to Emerge as an Important Pharmaceutical Manufacturing Center

##### Threat from Other Asian Countries

##### India to Emerge as a Major Hub for Biogenerics

##### Acute Therapy Class Leads the Market

**Table 59.** Leading Therapeutic Categories in the Indian Pharmaceutical Industry- Percentage Share Breakdown of Value Sales for Anti-infectives, Gastrointestinal, Cardiovascular, Respiratory, Minerals and Vitamins, Analgesics, Women's Health, Central Nervous System, Dermatology, and Others (includes corresponding Graph/Chart)

## Increase in Private Healthcare Services

### China

#### Chinese Pharma Industry Remains Immune to Global Crisis, for Now

#### Issues and Trends

#### Pharmaceutical Firms to Play Pivotal Role in Transforming Healthcare System

#### Brand Name Drugs to Exhibit Fastest Growth, While Generics Continue to Lead

#### Generics in China

#### Traditional Medicines – Substantial Share

**Table 60.** Leading Medicine Types in China (2005): Percentage share for Allopathic Medicines, Traditional Chinese Medicines (TCM), and Other Drugs (includes corresponding Graph/Chart)

## Underserved Markets Prompt Government to Foster Development

### Domestic EPO Market Booming, Domestic Players Continue their Domination

### Chinese Antipsychotics Market to Witness Substantial Growth

### Antidepressant Drugs to Exhibit Robust Sales

Indonesia

Market Features

Government-Enforced Pricing Control Over Essential Drugs

Distribution

Korea

Patent Expiries of Leading Drugs in South Korea: 2008 and 2009

Malaysia

Foreign Investments on the Rise

Domestic Market

Australia

Pharmaceutical Benefits Scheme

Government's Industry Development Programs

Outlook

Product Launches

Strategic Corporate Developments

Select Key Players

## **B. MARKET ANALYTICS**

**Table 61.** Asia-Pacific Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US\$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 62.** Asia-Pacific Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US\$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

## **6. LATIN AMERICA**

### **A. MARKET ANALYSIS**

Current and Future Analysis

Strategic Corporate Developments

### **B. MARKET ANALYTICS**

**Table 63.** Latin American Recent Past, Current & Future Analysis for Prescription Drugs

Market Analyzed with Annual Sales in US\$ Billion for Years 2006 through 2015  
(includes corresponding Graph/Chart)

**Table 64.** Latin American Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US\$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

## **7. REST OF WORLD**

### **A. MARKET ANALYSIS**

Current and Future Analysis  
Product Launches  
Strategic Corporate Developments

### **B. MARKET ANALYTICS**

**Table 65.** Rest of World Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US\$ Billion for Years 2006 through 2015  
(includes corresponding Graph/Chart)

**Table 66.** Rest of World Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US\$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

## **IV. COMPETITIVE LANDSCAPE**

Total Companies Profiled: 292 (including Divisions/Subsidiaries - 360)  
Region/CountryPlayers  
The United States  
Canada  
Japan  
Europe  
France  
Germany  
The United Kingdom  
Italy  
Rest of Europe

Asia-Pacific (Excluding Japan)

Latin America

Africa

## I would like to order

Product name: Prescription Drugs: Market Research Report

Product link: <https://marketpublishers.com/r/P3A41D04CB2EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P3A41D04CB2EN.html>